Evidence map›Paper›PMID 41114764›Full record

ReviewJournal of racial and ethnic health disparities2025

Sickle Cell Disease and Gene Therapy Among African Americans: A Dilemma and Challenge.

Elizabeth Armstrong-Mensah, Ato Kwamena Tetteh, Emmanuel Ofori, David Armstrong-Mensah

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of racial and ethnic health disparities, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Elizabeth Armstrong-MensahSchool of Public Health, Georgia State University, Atlanta, GA, 30303, USA. earmstrongmensah@gsu.edu.ORCID http://orcid.org/0000-0003-1026-7529
Ato Kwamena TettehCenter On Human Development, University of Oregon, Eugene, OR, USA.
Emmanuel OforiDepartment of Family Medicine, Dalhousie University, Yarmouth, NS, Canada.
David Armstrong-MensahCollege of Arts and Sciences, Georgia State University, Atlanta, GA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sickle cell disease (SCD) is a debilitating genetic disorder of the red blood cells. In severe cases, it may lead to pain, hospitalization, stroke, heart disease, organ damage, acute chest syndrome caused by blockages in the lungs, and chronic complications which may affect the kidneys, lungs, joints, and eyes. In the United States (US), about 100,000 people have SCD, with 90% being African American. Although the US Food and Drug Administration's recently approved groundbreaking base editing gene therapies of Casgevy and Lyfgenia have been declared promising in treating SCD, uptake for the therapies has been low. Though the treatment of SCD through gene therapy has sparked some excitement in the African American community, it is also causing a dilemma and challenges. This paper documents the dilemma and challenges associated with gene therapy among the African American SCD community and what can be done to address them.

Indexed as

African AmericansDilemmaGene therapyGene therapy challengesSickle cell disease

Identifiers

PMID41114764

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.